Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.56 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856767 | 0.91 | CASP6 (0.54) | CASP6GFERMEN1KMT2AMAPT | |
| SCHEMBL1779457 | 0.85 | KDM4E (0.59) | MEN1KMT2AKDM4ETP53PANK3 | |
| SCHEMBL12947249 | 0.83 | MAPT (0.53) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL28712422 | 0.83 | L3MBTL1 (0.66) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL18701870 | 0.83 | PANK3 (0.53) | MEN1KMT2AMAPTKDM4ETP53 | |
| SCHEMBL22914818 | 0.82 | ALDH1A1 (0.68) | MEN1KMT2ACYP2C9CYP1A2TSHR | |
| SCHEMBL2384959 | 0.82 | KDM4E (0.80) | KDM4ETP53PANK3ALDH1A1POLB | |
| SCHEMBL19049593 | 0.81 | DRD2 (0.59) | CASP6GFEREGLN2CYP1A2TSHR | |
| SCHEMBL22914742 | 0.81 | CTSS (0.46) | CASP6GFERMEN1KMT2AKDM4E | |
| SCHEMBL15009898 | 0.80 | MAPT (0.69) | MAPTKDM4ETP53PANK3CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112996513-B | Novel pyridazines | 勃林格殷格翰国际有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3873472-B1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230014173-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-19 | — | — | US | disclosed |
| US-11180472-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2021-11-23 | — | — | US | disclosed |
| EP-3873472-A1 | NOVEL PYRIDAZINES | Boehringer Ingelheim International GmbH (DE) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021013830-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2021013832-A1 | 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20200239434-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2020-07-30 | — | — | US | disclosed |
| US-20200131151-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-30 | — | — | US | disclosed |
| US-20200131151-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-04-30 | — | — | US | disclosed |
| US-10364232-B2 | Antibacterial compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2019-07-30 | — | — | US | disclosed |
| US-20180186768-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-05 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180472-B2 | Antibacterial compounds | FDPS, SQOR, NDUFS3 | CASP6 1026/4885GFER 2171/4885MEN1 2036/4885 |
| US-20210024492-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | CASP6 897/4885GFER 3589/4885MEN1 2373/4885 |
| US-20210024495-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | CASP6 897/4885GFER 3589/4885MEN1 2373/4885 |
| US-20230022770-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | CASP6 897/4885GFER 3589/4885MEN1 2373/4885 |
| US-10364232-B2 | Antibacterial compounds | FDPS, SQOR, NDUFS3 | CASP6 1026/4885GFER 2171/4885MEN1 2036/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | CASP6 2346/4885GFER 104/4885MEN1 4876/4885 |
| US-20180186768-A1 | Antibacterial Compounds | FDPS, SQOR, NDUFS3 | CASP6 1026/4885GFER 2171/4885MEN1 2036/4885 |
| US-20230014173-A1 | Antibacterial Compounds | FDPS, SQOR, NDUFS3 | CASP6 1026/4885GFER 2171/4885MEN1 2036/4885 |
| US-20200239434-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, SQOR, NDUFS3 | CASP6 1026/4885GFER 2171/4885MEN1 2036/4885 |
| US-20200131151-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | CASP6 897/4885GFER 3589/4885MEN1 2373/4885 |
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | CASP6 4684/4885GFER 3693/4885MEN1 970/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | CASP6 343/4885GFER 4595/4885MEN1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.